22nd February, 2022

To.

National Stock Exchange of India Limited

Exchange Plaza

Bandra Kurla Complex

Bandra (E), Mumbai – 400051

Scrip Code: MARKSANS

To,

BSE Limited

P. J. Towers

Dalal Street

Mumbai – 400 001

Scrip Code: **524404**

PRESS RELEASE

Marksans Pharma Limited announces UK MHRA approval for Bells Healthcare All in One Oral Solution.

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that UK MHRA has granted Market Authorisation to the Company's wholly owned subsidiary Bell Sons & Co. (Druggists) Limited for Bells Healthcare All in One Oral Solution.

Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg and Phenylephrine Hydrochloride Ph. Eur. 10.0 mg.

Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs.

This is the first generic approval by UK MHRA for the product.

Marksans will manufacture the products at its UK MHRA approved facility Bell Sons & Co. (Druggists) Limited in UK.

For Marksans Pharma Limited

Harshavardhan Panigrahi

Company Secretary

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Ltd